-+ 0.00%
-+ 0.00%
-+ 0.00%

Virax Biolabs Group Unit Enters Into Exclusive Multi-Country Commercial Supply Agreement With Fosun Diagnostics For ImmuneSelect Research-Use Immune Profiling Product Line

Benzinga·07/09/2026 11:34:33
Listen to the news

Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.

ImmuneSelect is Virax's commercially available research-use-only ("RUO") immune profiling product line and is distinct from ViraxImmune™, the Company's in-development diagnostic platform currently progressing through clinical and regulatory development.